+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Anticonvulsants Market: By Disease Treatment; By Drugs Type and By Geography - Forecast 2016-2021

  • ID: 3920152
  • Report
  • February 2016
  • Region: Global
  • 137 pages
  • IndustryARC
Anticonvulsants (also commonly known as antiepileptic drugs or as antiseizure drugs) are drugs that are used in the prevention or reduction of the severity and frequency of seizures in various types of epilepsy. Epilepsy can be defined as a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain. There several different types of anticonvulsants which may act on different receptors in the brain and have different modes of action.

This report identifies the anticonvulsants market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anticonvulsants market.

Globally North America dominated the market for anticonvulsants in 2015 due to highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy, and availability of skilled professionals for treating epilepsy. North America was followed by Europe and Asia-Pacific as the second and third largest markets respectively for anticonvulsants in 2015. Demand for anticonvulsants in Asia-Pacific is expected to witness fastest growth in the near future due to constantly increasing medical tourism in the countries such as China, India and Japan. Also increasing investment by the regional governments in the field of medical infrastructure is also expected to result in increased demand for anticonvulsants in the region.
This report on global anticonvulsants is segmented on the basis of various types of anticonvulsants, treated disease and market size in various geographical regions.

On the basis of types of anticonvulsants this report classified as follows covering all major types of anticonvulsants as follows: AMPA, Barbiturate, Benzodiazepine, Carbamate anticonvulsants, Carbonic anhydrase inhibitor, Dibenzazepine, Triazine and Others

On the basis of disease treated, anticonvulsants market is segmented as follows: Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety and Bipolar disorder

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anticonvulsants in each of the region.

This report identifies all the major companies operating in the global Anticonvulsants market. Some of the major companies’ profiles in detail are as follows:
Pfizer inc.
Novartis International AG
Abbott Laboratories
Johnson & Johnson
GlaxoSmithKline Pharmaceuticals Ltd

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
1. Anticonvulsants – Market Overview

2. Executive Summary

3. Anticonvulsants Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Anticonvulsants – Market Forces
4.1. Drivers
4.1.1. Increasing global awareness about the availability of anticonvulsants
4.2. Restraints
4.2.1. Large scale availability of cost effective generic drugs
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Anticonvulsants – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Global Anticonvulsants Market, By Treatment (2014-2021)
6.1. Epilepsy
6.2. Migraine
6.3. Fibromyalgia
6.4. Neuropathic pain
6.5. Anxiety
6.6. Bipolar disorder

7. Global Anticonvulsants Market, By Drugs Type (2014-2021)
7.1. AMPA
7.2. Barbiturate
7.3. Benzodiazepine
7.4. Carbamate anticonvulsants
7.5. Carbonic anhydrase inhibitor
7.6. Dibenzazepine
7.7. Triazine
7.8. Others

8. Global Anticonvulsants Market, By Geography (2014-2021)
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Anticonvulsants – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Top 10 Companies)
10.1. Pfizer inc.
10.1.1. Introduction
10.1.2. Financials
10.1.3. Key Insights
10.1.4. Key Strategy
10.1.5. Product Portfolio
10.1.6. SWOT Analysis
10.2. Novartis International AG
10.2.1. Introduction
10.2.2. Financials
10.2.3. Key Insights
10.2.4. Key Strategy
10.2.5. Product Portfolio
10.2.6. SWOT Analysis
10.3. Abbott Laboratories
10.3.1. Introduction
10.3.2. Financials
10.3.3. Key Insights
10.3.4. Key Strategy
10.3.5. Product Portfolio
10.3.6. SWOT Analysis
10.4. UCB
10.4.1. Introduction
10.4.2. Financials
10.4.3. Key Insights
10.4.4. Key Strategy
10.4.5. Product Portfolio
10.4.6. SWOT Analysis
10.5. Johnson & Johnson
10.5.1. Introduction
10.5.2. Financials
10.5.3. Key Insights
10.5.4. Key Strategy
10.5.5. Product Portfolio
10.5.6. SWOT Analysis
10.6. GlaxoSmithKline Pharmaceuticals Ltd
10.6.1. Introduction
10.6.2. Financials
10.6.3. Key Insights
10.6.4. Key Strategy
10.6.5. Product Portfolio
10.6.6. SWOT Analysis
10.7. Sunovion Pharmaceuticals, Inc
10.7.1. Introduction
10.7.2. Financials
10.7.3. Key Insights
10.7.4. Key Strategy
10.7.5. Product Portfolio
10.7.6. SWOT Analysis
10.8. Eisai Pharmaceuticals India Pvt. Ltd
10.8.1. Introduction
10.8.2. Financials
10.8.3. Key Insights
10.8.4. Key Strategy
10.8.5. Product Portfolio
10.8.6. SWOT Analysis
10.9. Bial
10.9.1. Introduction
10.9.2. Financials
10.9.3. Key Insights
10.9.4. Key Strategy
10.9.5. Product Portfolio
10.9.6. SWOT Analysis
10.10. Otsuka Pharmaceutical
10.10.1. Introduction
10.10.2. Financials
10.10.3. Key Insights
10.10.4. Key Strategy
10.10.5. Product Portfolio
10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Expert Insights
Note: Product cover images may vary from those shown